May 11, 2021 / 09:00PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst
Okay. Good afternoon, everyone. I'm Geoff Meacham, I'm the senior biopharma analyst here at BofA. And I have Olivia Brayer from my team with me as well. And welcome to the afternoon session for the Bofa Virtual Vegas Healthcare Conference. We are thrilled to end today with Bristol Myers. And speaking on behalf of Bristol, we have Chris Boerner, who is Executive VP and Chief Commercial Officer. Chris, thanks for joining us.
Christopher S. Boerner - Bristol-Myers Squibb Company - Executive VP & Chief Commercialization Officer
It's my pleasure to be here. Thanks for the invitation.
Questions and Answers:
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research AnalystAnd so maybe to kick it off at a higher level, Chris, how should we think about the cadence of growth over the course of this year? Is it a function of trying to see the Opdivo business reaccelerate? Is there an element of all the new launches